In terms of valuation, BioCryst Pharmaceuticals Inc’s market capitalization stands at $1.66 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company ...

BioCryst Pharmaceuticals Inc (BCRX) stock saw a decline, ending the day at $7.64 which represents a decrease of $-0.09 or -1.16% from the prior close of $7.73. The stock opened at $7.64 and touched a ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst (BCRX – Research Report) on January 21 and set a price target of $10.00.

Hidden gems in the biotech sector are reshaping healthcare with breakthroughs in personalized medicine and rare disease ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Evercore ISI raised the firm’s price target on BioCryst (BCRX) to $12 from $10 and keeps an Outperform rating on the shares. The company preannounced 2024 Orladeyo revenue of $437M, $2M ahead of the ...

Shares of BCRX stock opened at $7.93 on Monday. The stock has a 50 day moving average of $7.59 and a 200 day moving average of $7.59. The stock has a market cap of $1.64 billion, a P/E ratio of ...

BioCryst (NASDAQ:BCRX) released its preliminary 2024 revenue results, along with guidance for 2025. The company said it expects to report 2024 net revenue of $450M, up 36% from the prior year ...

BioCryst Pharmaceuticals projects 2025 ORLADEYO net revenue of $515-$535 million and total revenue of $540-$560 million. BioCryst Pharmaceuticals announced its preliminary unaudited ORLADEYO ...